Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2

Computer-aided drug design has become an integral part of drug discovery and development in the pharmaceutical and biotechnology industry, and is nowadays extensively used in the lead identification and lead optimization phases. The drug design data resource (D3R) organizes challenges against blinded experimental data to prospectively test computational methodologies as an opportunity for improved methods and algorithms to emerge. We participated in Grand Challenge 2 to predict the crystallographic poses of 36 Farnesoid X Receptor (FXR)-bound ligands and the relative binding affinities for two designated subsets of 18 and 15 FXR-bound ligands. Here, we present our methodology for pose and affinity predictions and its evaluation after the release of the experimental data. For predicting the crystallographic poses, we used docking and physics-based pose prediction methods guided by the binding poses of native ligands. For FXR ligands with known chemotypes in the PDB, we accurately predicted their binding modes, while for those with unknown chemotypes the predictions were more challenging. Our group ranked #1st (based on the median RMSD) out of 46 groups, which submitted complete entries for the binding pose prediction challenge. For the relative binding affinity prediction challenge, we performed free energy perturbation (FEP) calculations coupled with molecular dynamics (MD) simulations. FEP/MD calculations displayed a high success rate in identifying compounds with better or worse binding affinity than the reference (parent) compound. Our studies suggest that when ligands with chemical precedent are available in the literature, binding pose predictions using docking and physics-based methods are reliable; however, predictions are challenging for ligands with completely unknown chemotypes. We also show that FEP/MD calculations hold predictive value and can nowadays be used in a high throughput mode in a lead optimization project provided that crystal structures of sufficiently high quality are available.

[1]  Julien Michel,et al.  Blinded predictions of binding modes and energies of HSP90-α ligands for the 2015 D3R grand challenge. , 2016, Bioorganic & medicinal chemistry.

[2]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[3]  Shuai Liu,et al.  D3R grand challenge 2015: Evaluation of protein–ligand pose and affinity predictions , 2016, Journal of Computer-Aided Molecular Design.

[4]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[5]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[6]  Kenneth D. Jordan,et al.  Comparison of Density Functional and MP2 Calculations on the Water Monomer and Dimer , 1994 .

[7]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[8]  Peter A. Kollman,et al.  Free energy calculations on protein stability: Thr-157 .fwdarw. Val-157 mutation of T4 lysozyme , 1989 .

[9]  Hans Richter,et al.  Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. , 2009, Bioorganic & medicinal chemistry letters.

[10]  Shuai Liu,et al.  Lead optimization mapper: automating free energy calculations for lead optimization , 2013, Journal of Computer-Aided Molecular Design.

[11]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[12]  B. Brooks,et al.  An analysis of the accuracy of Langevin and molecular dynamics algorithms , 1988 .

[13]  Z. Xiang,et al.  On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.

[14]  Ruhong Zhou,et al.  Single mutation induced H3N2 hemagglutinin antibody neutralization: a free energy perturbation study. , 2008, The journal of physical chemistry. B.

[15]  Jennifer L. Knight,et al.  Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors. , 2013, Journal of chemical theory and computation.

[16]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[17]  Charles H. Bennett,et al.  Efficient estimation of free energy differences from Monte Carlo data , 1976 .

[18]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[19]  Gerhard Hummer,et al.  Free Energy of Ionic Hydration , 1996 .

[20]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[21]  Francisco Adasme-Carreño,et al.  Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations , 2016, Journal of Computer-Aided Molecular Design.

[22]  Mika A. Kastenholz,et al.  Computation of methodology-independent ionic solvation free energies from molecular simulations. I. The electrostatic potential in molecular liquids. , 2006, The Journal of chemical physics.

[23]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[24]  Yong Li,et al.  The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism , 2013, Nature Communications.

[25]  W. L. Jorgensen Efficient Drug Lead Discovery and Optimization , 2009 .

[26]  B. Berne,et al.  Replica exchange with solute scaling: a more efficient version of replica exchange with solute tempering (REST2). , 2011, The journal of physical chemistry. B.

[27]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[28]  Woody Sherman,et al.  ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..

[29]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[30]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[31]  B. Berne,et al.  Replica exchange with solute tempering: a method for sampling biological systems in explicit water. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. W. Becker,et al.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation , 2008, Proceedings of the National Academy of Sciences.

[33]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[34]  R. Abagyan,et al.  Flexible ligand docking to multiple receptor conformations: a practical alternative. , 2008, Current opinion in structural biology.

[35]  Z. Cournia,et al.  Free Energy Calculations Reveal the Origin of Binding Preference for Aminoadamantane Blockers of Influenza A/M2TM Pore. , 2013, Journal of chemical theory and computation.

[36]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[37]  Lingle Wang,et al.  On achieving high accuracy and reliability in the calculation of relative protein–ligand binding affinities , 2012, Proceedings of the National Academy of Sciences.

[38]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[39]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[40]  Atli Thorarensen,et al.  Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free‐Energy Perturbation (FEP) , 2016, ChemMedChem.

[41]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[42]  Heather A Carlson,et al.  Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.

[43]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[44]  Franz Schuler,et al.  Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. , 2011, Bioorganic & medicinal chemistry letters.

[45]  Peter A. Kollman,et al.  Free energy perturbation simulations of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor , 1989 .

[46]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[47]  Zoe Cournia,et al.  Structural Characterization and Computer‐Aided Optimization of a Small‐Molecule Inhibitor of the Arp2/3 Complex, a Key Regulator of the Actin Cytoskeleton , 2012, ChemMedChem.

[48]  B. Kuhn,et al.  Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. , 2011, Bioorganic & medicinal chemistry letters.

[49]  W. L. Jorgensen,et al.  Monte Carlo simulation of differences in free energies of hydration , 1985 .

[50]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[51]  Peter A. Kollman,et al.  Computer modeling of the interactions of complex molecules , 1990 .

[52]  Shawn P. Williams,et al.  FXR agonist activity of conformationally constrained analogs of GW 4064. , 2009, Bioorganic & medicinal chemistry letters.

[53]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[54]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[55]  Shawn P Williams,et al.  Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. , 2009, Bioorganic & medicinal chemistry letters.

[56]  Mika A. Kastenholz,et al.  Computation of methodology-independent ionic solvation free energies from molecular simulations. II. The hydration free energy of the sodium cation. , 2006, The Journal of chemical physics.

[57]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[58]  G. B. Wisely,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. , 2011, Bioorganic & medicinal chemistry letters.

[59]  James Andrew McCammon,et al.  Ligand-receptor interactions , 1984, Comput. Chem..

[60]  Peng Liu,et al.  Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor* , 2015, The Journal of Biological Chemistry.

[61]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[62]  Jing Zhang,et al.  Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences , 2013 .

[63]  M. Evans,et al.  Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. , 2010, Journal of medicinal chemistry.

[64]  Woody Sherman,et al.  Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring , 2011, J. Chem. Inf. Model..

[65]  Thomas Fox,et al.  Accuracy Assessment and Automation of Free Energy Calculations for Drug Design , 2014, J. Chem. Inf. Model..

[66]  Clara D. Christ Binding affinity prediction from molecular simulations: A new standard method in structure-based drug design? , 2016 .

[67]  William L. Jorgensen,et al.  Free energy calculations: a breakthrough for modeling organic chemistry in solution , 1989 .

[68]  I. Kuntz,et al.  Molecular docking to ensembles of protein structures. , 1997, Journal of molecular biology.

[69]  Edward D Harder,et al.  How To Deal with Multiple Binding Poses in Alchemical Relative Protein–Ligand Binding Free Energy Calculations , 2015, Journal of chemical theory and computation.

[70]  Herman van Vlijmen,et al.  Computational chemistry at Janssen , 2017, Journal of Computer-Aided Molecular Design.

[71]  Pratyush Tiwary,et al.  Prediction of Protein-Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations. , 2016, Journal of chemical theory and computation.

[72]  Claudio Chuaqui,et al.  Structural Interaction Fingerprints: A New Approach to Organizing, Mining, Analyzing, and Designing Protein–Small Molecule Complexes , 2006, Chemical biology & drug design.

[73]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .